RIGL Q2 2026 Earnings Call Summary

1Key Financial Results and Metrics

Net Product Sales: $67 million, a 14% increase year-over-year, with TAVALISSE generating $47.4 million (up 18%), GAVRETO at $10.7 million (slight decline), and REZLIDHIA at $8.9 million (up 27%).

Total Revenues: $78.7 million, including $11.7 million in collaboration revenues.

Net Income: $17.3 million, down from $59.6 million in Q2 2025, largely due to a $40 million non-cash revenue in the previous year.

Cash Position: $95.3 million, down from $155 million at the end of 2025.

Cost of Sales: Approximately $8.5 million, with total expenses rising to $55.1 million, reflecting increased R&D costs.

2Strategic Updates and Business Highlights

VEPPANU In-Licensing: Rigel completed the in-licensing of VEPPANU (vepdegestrant), an FDA-approved PROTAC for ER-positive, HER2-negative breast cancer, expected to launch in mid-August.

Product Portfolio Expansion: The company is transitioning from a single-product focus to a diversified oncology and hematology company, with VEPPANU anticipated to be a significant growth driver.

R289 Development: Ongoing trials for R289 in lower-risk myelodysplastic syndromes (MDS) are progressing, with a readout expected by year-end.

3Forward Guidance and Outlook

2026 Revenue Guidance: Total revenues projected at $285 million to $295 million, with net product sales (excluding VEPPANU) expected between $255 million and $265 million.

Positive Net Income: Anticipated for the full year while funding existing and new clinical programs.

Future Growth: Rigel aims for a compound annual growth rate of approximately 35% from 2022 to 2026, leveraging the new product pipeline.

4Bad News, Challenges, or Points of Concern

Declining Net Income: The significant drop in net income compared to the previous year raises concerns about profitability sustainability.

Cash Burn: The decrease in cash reserves may limit operational flexibility and funding for future projects.

Market Competition: The competitive landscape for breast cancer treatments, particularly with the rise of oral SERDs, poses a risk to VEPPANU's market penetration.

5Notable Q&A Insights

Commercial Focus on VEPPANU: Management emphasized VEPPANU as the lead focus for commercial efforts, with strategies in place to ensure support for existing products like TAVALISSE and REZLIDHIA.

Market Opportunity for VEPPANU: The estimated market opportunity for VEPPANU is over $1 billion, targeting 20,000 patients annually in the second-line ESR1-mutated breast cancer segment.

Collaboration Highlights: The MD Anderson collaboration was highlighted as particularly promising for R289, with multiple ongoing trials.

Sales Expectations: Management refrained from providing specific sales guidance for VEPPANU until after Q3, indicating a cautious approach to forecasting. This summary encapsulates the key aspects of Rigel's Q2 2026 earnings call, highlighting financial performance, strategic initiatives, and future outlook while addressing potential challenges and insights from the Q&A session.